Vironix AI

Vironix AI

Remote patient monitoring for chronic care

Overview

Vironix AI offers a virtual care platform for healthcare providers to remotely monitor patients with chronic diseases using RPM, RTM, CCM, PCM, CCCM and a staff monitoring service. The system collects home health data and uses validated algorithms and proprietary scores to risk-stratify patients, directing care where needed, with an automated CMS claims workflow to speed reimbursement. It differentiates itself by offering the full suite of chronic care programs plus risk stratification and outsourcing of monitoring staff. The goal is to improve patient outcomes through at-home monitoring and timely interventions while helping providers extend care and secure reimbursement.

About Vironix AI

Simplify's Rating
Why Vironix AI is rated
C+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

11-50

Company Stage

Seed

Total Funding

$280K

Headquarters

New York City, New York

Founded

2020

Get referred to Vironix AI

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vironix posted FDA clearance for multi-condition AI detection on February 19, 2026.
  • Website updates on August 8, 2026 signal active product marketing and momentum.
  • Customer mentions include Georgia Kidney Associates and Bodimetrics, showing real provider adoption.

What critics are saying

  • $3.38 million total funding limits salesforce, clinical trials, and reimbursement defense.
  • Competitors like CareSignal, Cadence, and Current Health already own provider trust.
  • A CMS reimbursement rule change in 2026 can crush the revenue model overnight.

What makes Vironix AI unique

  • Single workflow bundles RPM, CCM, RTM, PCM, CCCM, and APCM with embedded staff.
  • Vironix claims 95% work handled, 30-day implementation, and automatic CMS billing.
  • Oxford collaboration on CKD and CHF prediction adds academic validation credibility.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$280k

Below

Industry Average

Funded Over

1 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Below Average

Industry standards

$3.3M
$280k
Vironix AI
$1.5M
Slack
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood

Benefits

Health Insurance

Stock Options

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

2%

2 year growth

2%
Vironix AI
Jun 24th, 2025
Remote Monitoring Leadership Council Launches!

Vironix Health celebrates the launch of the Remote Monitoring Leadership Council, a new alliance of digital health CEOs united to advance tech-enabled care and champion the expansion of Remote Patient Monitoring (RPM) across the country.

PMLive
Aug 25th, 2023
Vironix and Oxford University partner to advance chronic kidney disease monitoring

The collaboration comes a year after Vironix announced its partnership with Oxford University to develop novel prediction methods for proactive intervention in congestive heart failure.

PR Newswire
Aug 24th, 2023
Breakthroughs Using Ai For Chronic Kidney Disease Monitoring: Vironix Health And Oxford University

AUSTIN, Texas, Aug. 24, 2023 /PRNewswire/ -- Vironix Health Inc., an innovative leader in AI-powered remote patient monitoring applications for healthcare providers, is bolstering its alliance with the University of Oxford's Mathematical Institute. The collaboration aims squarely at advanced prediction of Chronic Kidney Disease (CKD) progression.Oxford UniversityBuilding on the triumph of last year's synthetic patient data generation project, the partners are setting their sights on CKD, a medical challenge marked by gradual kidney function deterioration. Early interventions leveraging AI can amplify patient well-being, decelerate the disease progression, and reduce healthcare costs. Dr. Sumanth Swaminathan, CEO of Vironix Health, commented on the partnership's potential, remarking, "Vironix is committed to innovating preventive care technologies that prioritize validation through scientific rigor and peer review

HRNXT Media
Mar 15th, 2023
Former BookMyShow CTO Mahesh Vandi Chalil appointed Chief Product and Technology Officer at Cyble | hrnxt.com

Vironix Health, a digital health company, has announced the appointment of Mahesh Visvanathan, MS/MBA as Chief Operations and Business Development Officer to lead its strategic partnership and commercialization strategy.

Recently Posted Jobs

Sign up to get curated job recommendations

Vironix AI is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →